Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 281-876-3 | CAS number: 84051-87-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- reproductive toxicity, other
- Remarks:
- organ toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Justification for type of information:
- Data from secondary source
Data source
Reference
- Reference Type:
- secondary source
- Title:
- Twenty-eight-day Repeat Dose Oral Toxicity Test of test material in Rats
- Author:
- J-check
- Year:
- 2 010
- Bibliographic source:
- Japanese Ministry of Health; Labour and Welfare,2010
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: As mentioned below
- Principles of method if other than guideline:
- Twenty-eight-day Repeat Dose Oral Toxicity study of test material was performed in Rats
- GLP compliance:
- not specified
- Limit test:
- no
- Justification for study design:
- No data available
Test material
- Reference substance name:
- Disperse red 206
- Cas Number:
- 26630-87-5
- Molecular formula:
- C28H26ClN5O5S
- IUPAC Name:
- Disperse red 206
- Details on test material:
- - IUPAC Name: Disperse Red 206
- Smiles: CCN(CCO)c1ccc(N=NC2=N{+}(C)(.O{-}C(C)=O)c3ccc(OC)cc3S2)cc1
- Molecular formula : C21H26N4O4S
- Substance type: Organic
- Physical state: reddish brown odorless powder
- Purity: 97.65%
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crj: CD (SD)IGS
- Details on species / strain selection:
- No data available
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Details on test animals and env. conditions
TEST ANIMALS
- Source: Charles River Co., Ltd. Atsugi Breeding Center Co., Ltd.
- Age at study initiation: 5 weeks of age
- Weight at study initiation: (P) Males: x-x g; Females: x-x g; (F1) Males: x-x g; Females: x-x g
- Fasting period before study:
- Housing: The animals were placed in a bracket-type metallic wire mesh floor cage
- Use of restrainers for preventing ingestion (if dermal): yes/no
- Diet (e.g. ad libitum): gamma-irradiated solid feed CRF-1 (Oriental Yeast Co., Ltd.) ad libitum
- Water (e.g. ad libitum): drinking water was freely ingested by Sapporo city tap water
- Acclimation period: 1 week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 to 24 ° C
- Humidity (%):45 to 68%
- Air changes (per hr): 10 to 15 times / hour
- Photoperiod (hrs dark / hrs light): an illumination time of 8 to 20 hours
IN-LIFE DATES: From: To:
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5% methyl cellulose aqueous solution
- Details on exposure:
- Details on exposure
PREPARATION OF DOSING SOLUTIONS:
The test substance was suspended using a 0.5% methyl cellulose aqueous solution.
DIET PREPARATION
- Rate of preparation of diet (frequency):No data available
- Mixing appropriate amounts with (Type of food)
- Storage temperature of food: No data available
VEHICLE
- Justification for use and choice of vehicle (if other than water): corn oil
- Concentration in vehicle: 0, 250, 500, and 1000 mg / kg
- Amount of vehicle (if gavage): 5 mL / kg
- Lot/batch no. (if required): No data available
- Purity: No data available - Details on mating procedure:
- No data available
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
- Details on study schedule:
- No data available
Doses / concentrations
- Remarks:
- 0, 250, 500, and 1000 mg / kg
- No. of animals per sex per dose:
- Total: 42 male and 42 female
0 mg / kg:7 male and 7 female
250 mg / kg:7 male and 7 female
500 mg / kg:7 male and 7 female
1000 mg / kg:7 male and 7 female
Recovery group
0 mg / kg:7 male and 7 female
1000 mg / kg:7 male and 7 female - Control animals:
- yes, concurrent vehicle
- Details on study design:
- No data available
- Positive control:
- No data available
Examinations
- Parental animals: Observations and examinations:
- Parental animals observation and examinations
CAGE SIDE OBSERVATIONS: yes
DETAILED CLINICAL OBSERVATIONS: Yes
Time schedule: daily
BODY WEIGHT: Yes
Time schedule for examinations: Body weight of individual animals were measured on days 1, 7, and 14 before administration on days 1, 2, 7, 14, 21 and 28, and on the autopsy day of each day after the end of each period
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):Yes food intake of individual animals were measured on days 1, 7, and 14 before administration on days 1, 2, 7, 14, 21 and 28, and on the autopsy day of each day after the end of each period,Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data: No data available
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data
Time schedule for examinations:
OTHER: - Oestrous cyclicity (parental animals):
- No data available
- Sperm parameters (parental animals):
- Parameters examined in [all/P/F1/F2] male parental generations:
testis weight and epididymis weight were observed - Litter observations:
- No data available
- Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals
- Maternal animals: All surviving animals
GROSS NECROPSY:yes
- Gross necropsy consisted of [external and internal examinations including the cervical, thoracic, and abdominal viscera.]
HISTOPATHOLOGY / ORGAN WEIGHTS: yes
The tissues indicated in Table [#] were prepared for microscopic examination and weighed, respectively. - Postmortem examinations (offspring):
- No data available
- Statistics:
- Quantitative items of urinalysis (excluding urine specific gravity), hematological test (excluding percentage of leukocytes), blood chemistry test, results of absolute and relative weight of organs, body weight, weight gain and rate of increase, We analyzed equi dispersibility by Bartlett's test method, and analyzed by one-way analysis of variance in the case of equal variance and by Kruskal-Wallis's test in case of unequal variance. If a significant difference is found as a result of one-way ANOVA, Dunnett's test method is used, and if there is a significant difference as a result of analysis by the Kruskal-Wallis method, Mann-Whitney's U- , And compared with the control group, respectively.
For the qualitative items of urinalysis, the results of urine specific gravity and white blood cell percentage, the tendency of each group is analyzed by the Kruskal-Wallis test method, and when a significant difference is
observed, the Mann-Whitney U-test method is used And compared with controls. For each percentage of
leukocytes, average values and standard deviations were also calculated. Regarding the comparative test with the control group, statistically significant less than the risk ratio of 5% was taken. - Reproductive indices:
- No data available
- Offspring viability indices:
- No data available
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No abnormality was observed in both sexes in each administration group in either administration period or recovery period.
- Dermal irritation (if dermal study):
- not specified
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Only the males in the 250 mg / kg administration group showed significant increase in body weight gain and body weight gain during 28 days of administration, but not a dose-dependent change.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Only the males in the 250 mg / kg administration group showed a significant increase compared with the control group on the 28th administration but not the dose-dependent change.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- A significant lower value was found in males of the group receiving 250 mg / kg or more in the γ-globulin fraction ratio as compared with the control group, and at the end of the recovery period, females with a dose of 1000 mg / kg showed significant High level was recognized.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- There was no significant change in each treatment group of males and females as compared with the control group in either the administration period or the recovery period.
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Only mild changes such as kidney, liver, pituitary gland and the like were observed in one males and two females in the 1000 mg / kg administration group. Even at the end of the recovery period, only mild changes were observed in the lungs, liver, kidneys, etc. of 3 males in the 1000 mg / kg administration group
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- not specified
- Reproductive function: sperm measures:
- not specified
- Reproductive performance:
- not specified
Details on results (P0)
Effect levels (P0)
- Dose descriptor:
- NOAEL
- Effect level:
- 500 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- body weight and weight gain
- food consumption and compound intake
- haematology
- clinical biochemistry
- organ weights and organ / body weight ratios
- gross pathology
- histopathology: non-neoplastic
- Remarks on result:
- other: No effects on reproductive organ weight was observed
Target system / organ toxicity (P0)
- Critical effects observed:
- not specified
- System:
- other: not specified
- Organ:
- not specified
- Treatment related:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- not specified
- Dermal irritation (if dermal study):
- not specified
- Mortality / viability:
- not specified
- Body weight and weight changes:
- not specified
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Histopathological findings:
- not specified
- Other effects:
- not specified
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not specified
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not specified
Effect levels (F1)
- Dose descriptor:
- other: not specified
- Generation:
- other: not specified
- Based on:
- not specified
- Sex:
- not specified
- Basis for effect level:
- other: not specified
- Remarks on result:
- not measured/tested
Target system / organ toxicity (F1)
- Critical effects observed:
- not specified
- System:
- other: not specified
- Organ:
- not specified
- Treatment related:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
- Treatment related:
- not specified
- Relation to other toxic effects:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Applicant's summary and conclusion
- Conclusions:
- No Observed Adverse Effect Level (NOAEL) was considered to be 500mg/kg/day, Whenmale and female Crj:CD(SD)IGS rats were treated with test material orally.
- Executive summary:
The reproductive organ toxicity study of test material was performed using twenty-eight-day Repeat Dose Oral Toxicity study of test material in Crj: CD (SD)IGS male and female rats. The test material was suspended using a 0.5% methyl cellulose aqueous solutionand administeried in dose concentration 0, 250, 500, and 1000 mg / kg orally for 28 days. Each dose group and recovery group contain 7 male and 7 female. Doses were selected on preliminary study in which male and female SD rats were administered 0, 250, 500 and 1000 mg / kg for 14 days, Body weight and food intake of individual animals were measured on days 1, 7, and 14 before administration on days 1, 2, 7, 14, 21 and 28, and on the autopsy day of each day after the end of each period, All the cases were autopsied on day 28 of administration or the next day after recovery 14 days.
No abnormality was observed in both sexes in each administration group in either administration period or recovery period. Only the males in the 250 mg / kg administration group showed significant increase in body weight gain and body weight gain during 28 days of administration, but not a dose-dependent change. Only the males in the 250 mg / kg administration group showed a significant increase in food intake compared with the control group on the 28th administration but not the dose-dependent change. There was no significant change in Urinalysis each treatment group of males and females as compared with the control group in either the administration period or the recovery period. Male of 250 mg / kg or higher administration group and female of 500 mg / kg or more administration group were reddish purple jejunum ileum contents, dark greening of contents of cecum in males and females of 250 mg/ kg or more administered group , Pale reddening of jejunum ileum and intraabdominal fat tissue were observed. These changes showed an increase in the number of cases as the dose increased and it was judged that the change in color tone itself had no toxicological significance.
Significant higher values of absolute and relative weights of liver in male of 250 mg / kg or more in comparison with control group, significant lower value of absolute and relative weight of thymus in males and females of 500 mg / kg administered group Significantly high values of relative weight of liver, high value trend of absolute weight, significant low value of ovarian relative weight, low value trend of absolute weight were observed in females at low trend, 1000 mg / kg administration group, recovery At the end of the period, a significant high value of the absolute weight of the liver, a high value tendency of the relative weight, a low tendency of the absolute weight of the spleen, and a significant low value of the relative weight were observed in the male of 1000 mg / kg administration group. Besides, a significant high value of the absolute weight of the adrenal glands was seen in the males of the 250 mg / kg administration group, but it was not a dose-dependent change, and at the end of the recovery period female of 1000 mg / kg administration group received pituitary Significant lower values of absolute and relative weights were observed, but not changed at the end of the administration. Only mild changes such as kidney, liver, pituitary gland and the like were observed in one males and two females in the 1000 mg / kg administration group. Even at the end of the recovery period, only mild changes were observed in the lungs, liver, kidneys, etc. of 3 males in the 1000 mg / kg administration group. As no effects on reproductive organ weight was observed at 500mg/kg dose group hence,No Observed Adverse Effect Level (NOAEL) was considered to be 500mg/kg/day, Whenmale and femaleCrj:CD(SD)IGS rats were treated with test material orally.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.